• Email
  • Print
  • Share
  • Text
Highlight Glossary Terms
  • Dana-Farber Blog

    • Insight Blog screenshot Insight features the latest in cancer care and research news from Dana-Farber.
    • Read the blog 
  • Dana-Farber Facts

    • Dana-Farber 2015 Facts brochureFind statistics on Dana-Farber's patient care, fundraising initiatives and achievements, and phone numbers for patients and families.
    • View Dana-Farber Facts 
  • Dana-Farber View Book

    • Dana-Farber 2011 Viewbook coverThis 24-page magazine gives an overview of Dana-Farber, focusing on its equal investment in research and patient care.
    • View Dana-Farber View Book 
  • The Cancer Treatment Revolution

    • The Cancer Treatment Revolution book cover Dr. David Nathan, acclaimed pediatric hematologist and Dana-Farber's president from 1995 – 2000, recounts that history's triumphs and struggles in his book, The Cancer Treatment Revolution.

Dana-Farber Spotlight

Sign up to receive Dana-Farber Spotlight, our email newsletter.
View the current issue
Subscribe now
Unsubscribe from mailings

Media Contacts

Ellen Berlin
Director of Media Relations

Molly McHale
Associate Director of Media Relations


Top News Releases

Carlos Rodriguez-Galindo, MD
  • October 05, 2015
  • Disparities in outcomes for children with rare eye cancer suggest unequal access to primary care
  • Disparities in outcomes for children with retinoblastoma — a rare eye tumor usually discovered in routine pediatric check-ups — suggest unequal access to primary care, researchers from Dana-Farber/Boston Children’s Cancer and Blood Disorders Center report in a study published in the journal JAMA Pediatrics. Although virtually all the children in the study survived, Hispanic children and children who lived in disadvantaged areas were more likely to lose an eye due to late diagnosis.
Dana-Farber's Yawkey Center for Cancer Care
Jean Zhao, PhD
Toni K. Choueiri, MD
  • September 25, 2015
  • New drug improves outcome in treatment resistant kidney cancer
  • A new drug for renal cell carcinoma slowed the growth of advanced kidney cancer in patients who became resistant to the first-line therapies that had previously kept it in check, according to results from a clinical trial led by Dana-Farber Cancer Institute.

Dana Farber In the News


    Image Alt Text
    Image Alt Text
    Image Alt Text